Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
UCB SA (EBR: UCB) bets $1.15 bn on Neurona Therapeutics to push epilepsy treatment beyond symptom control
Read More Hotel and Hospitality Marston’s PLC (LSE: MARS) Q1 update shows festive resilience as format refresh and event-driven footfall fuel FY2026 confidence Marston’s Q1 update shows festive sales growth and strong pub rollout momentum. Find out what it means for FY2026 profits, margins, and investor sentiment. byVenkateshJanuary 28, 2026